Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Adjuvant Atezolizumab Plus Bevacizumab Strike Out in HCC
The initial results of the IMbrave050 trial raised hopes that an effective adjuvant regimen for hepatocellular carcinoma (HCC) might finally have arrived. Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor bevacizumab after…
English